Chongqing Peg-Bio Biopharm Co., Ltd.
8
3
3
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
13%
1 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
Role: lead
Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition
Role: lead
A Study of FT1 in Healthy Adult Volunteers
Role: lead
A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients
Role: lead
Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
Role: lead
A Study of PN20 in Healthy Adult Volunteers
Role: lead
A Study of PD5K3 in Healthy Adult Volunteers
Role: lead
A Study of PJ009 in Healthy Adult Volunteers
Role: lead
All 8 trials loaded